Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012"

Transcription

1 How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Disclosures No conflicts of interest to disclose Updates in the Management of HypertensionIn the Elderly Antoine T. Jenkins, Pharm.D., BCPS Assistant Professor of Pharmacy Practice Chicago State University College of Pharmacy Internal Medicine Pharmacy Specialist Roseland Community Hospital, Chicago, IL Learning Objectives Identify key recommendations from the ACCF/AHA 2011 Consensus Statement on Hypertension in the Elderly. Discuss the key clinical trials specific to this population of hypertensive patients. Define the role of the pharmacist in managing hypertension in patients of advanced age. Hypertension: Nationwide Dilemma Effects 1 in 3 US adults Serves as a gateway condition for more serious CV aliments Direct and indirect costs associated with HTN were ~ $73 billion Prevalence increases with aging Ethnicity Gender Circulation 2010;121:e1-e170. Circulation 2009.; 119:e Hypertension in the Elderly: Specific Concerns Isolated systolic hypertension pulse pressure Pseudohypertension Labile hypertension White coat hypertension Orthostasis Postprandial hypotension Secondary causes Drug Induced causes Hypertension In the Elderly: What s Currently Recommended? Recommendations from Internationally Published Guidelines Source Target BP Drug Selection Other Comments JNC VII None specifically Same as younger individuals. Treatment should not be withheld in stated Two drugs required for most patients Weight loss and Na + beneficial the elderly; therapy should not be withheld on the basis of age. AHA/ACC JNC-VII Complete Report 2003 NIH Publicatio Circulation 2007;115:

2 Hypertension In the Elderly: What s Currently Recommended? Recommendations from Internationally Published Guidelines Source Target BP Drug Selection Other Comments ESC/ESH < 140/90 mm Hg (if tolerated) Thiazides, CCBs, ACEs/ARBs, BBs Two drug needed for most CHEP < 140/90 mm Hg Thiazides, CCBs, ACEs/ARBs, BBs Two drug needed for most Avoid BBs (> 60 yrs as first line) Although benefits of treatment in those 80 yrs old are inconclusive, successful treatment should not be stopped Caution in frail individuals and those with orthostasis European Heart Journal (2007) 28, Hypertension in the Elderly: Review of Major Trials Major Hypertensive Trials Involving Elderly Patients Trial STOP (Swedish Ti Trial lin Old Patients with HTN) n=1627 SHEP (Systolic HTN in the Elderly Program) n=4736 (Age Range) 76 yrs (70 84 yrs) 72 yrs (60 to > 80 yrs) Starting BP (Goal BP) Treatment ( Mean Duration) Outcomes 195/102 mm Hg (<160/95 Pindolol, metoprolol, Stroke, MI, and CV death mm H) Hg) atenolol lor HCTZ + (p=0.0031) 0031) and amiloride or stroke morbidity/ placebo (65 mos) mortality (p=0.0081) 170/77 mm Hg (SBP< 160 or < 20 mm Hg from baseline) Cholrothialidone ± atenolol or placebo (4.5 yrs) fatal/nonfatlal stroke (p=0.0003). CV morbidity/ mortality Lancet 1991; 338: JAMA 1991; 265: Hypertension in the Elderly: Review of Major Trials Major Hypertensive Trials Involving Elderly Patients Trial (Age Range) Starting BP (Goal BP) Treatment (Mean Duration) Outcomes Sys Eur (Systolic (y HTN 70 yrs ( 60 yrs) 174/86 mm Hg (SBP < 150 or < Nitrendipine ± enalapril ±HCTZ total stroke by 42% in the Elderly) n= mm Hg from baseline) or placebo (2 yrs) (p=0.003). fatal/nonfatal CV endpoints by 31% (p=0.001) MRC (Medical Research Council Trial) n= yrs (65 74) 184/91 mm Hg (SBP 150 or 160 mm Hg) HCTZ or atenolol ± amiloride or placebo (5.8 yrs) total stroke and all CV events (all stat. sig) Lancet 1997; 350: BMJ 1992; 304: Questions That Still Need Answering? What is an ideal BP goal for the elderly? < 80 yrs old? 80 yrs old? Do the benefits of lowering BP outweigh hthe potential risks? When can BP lowering potentially cause harm in the elderly? What is the best treatment regimen for this population? ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents What is an ideal BP goal for the old and the very old? Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension 2

3 Uncomplicated vs. Complicated HTN? Age of the patient? Patients yrs: BP goal < 140/90 mm Hg. Goal may differ depending on presence of compelling indications. Patients 80 yrs: SBP of mm Hg, if tolerated, is acceptable. SBP 150 maybe acceptable in some cases. Aggressive BP goals for compelling indications are still reasonable only if tolerated Ensure usage of best clinical judgment HYVET (Hypertension in the Very Elderly Trial) 3,845 patients from global study sites 80 yrs of age with sustained SBP 160 mm Hg Europe Asia Australia Africa Indapamide ± perindopril (n=1933) HYVET: Study Population/Procedures 3845 patients randomized to either active treatment or placebo BP Target: <150/80 mm Hg Key Baseline Characteristics 83 yrs Mean BP 173/90 mm Hg Presence of CVD/DM 12%/7% Placebo (n=1912) Primary Outcomes Total strokes Secondary Outcomes Death from stroke Death from any cause Death CV causes HYVET: Endpoints HYVET: Results Do elderly patients reap benefits from BP lowering therapy? 3

4 ACCOMPLISH Trial (Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension) 11, 506 patients at high risk for CV events: 60 yrs of age, with a SBP 160 mm Hg or currently on antihypertensive therapy, plus with evidence of CV or renal disease or target organ damage yrs of age with evidence of two or more of CV diseases or target organ damage present N Engl J Med 2008; 359: Am J Hypertens 2004; 17: ACCOMPLISH: Study Population/ Procedures 11, 506 Patients Received Combination BP Therapy Mean BP Predominate Study Region BP Targets: < 140/90 mm Hg or < 130/80 mm Hg Key Baseline Characteristics 68 yrs 145/80 mm Hg 70% sites in United States Benazepril Amlodipine Group (n=5744) Benazepril HCTZ Group (n=5762) ACCOMPLISH: Endpoints Primary Outcomes Composite of CV events and death from CV causes Evaluation of individual components Death from CV causes Hosp. from unstable angina TtlMI Total Revascularization Total Stroke Resuscitation from cardiac arrest Prespecified subgroups (age, gender, diabetes) Secondary Outcomes Composite of death from CV events, nonfatal MI/stroke ACCOMPLISH: Results SHEP Trial Follow Up (Association Between Chlorthalidone Treatment of Systolic Hypertension and Long Term Survival) Objective: To assess the legacy effect of active treatment 22 yrs after the conclusion of the trial. Recap of SHEP Study: 4736 participants 60 yrs old with systolic HTN Baseline Characteristics: : 72 yrs old PMH: 5% had MI, ~1% had Mean BP: 170/76 mm Hg Smoking Status: 12% smoked CVA, 10% had DM JAMA 2011; 306 (23): SHEP Follow Up Trial Recap of SHEP Active Group: Chlorthalidone ± atenolol Placebo Group Length of Study: 4.5 yrs Method of analysis Evaluation of National Death Index for mortality and cause of death through Dec 2006 Primary Outcomes CV Death All Cause Mortality 4

5 SHEP Follow Up Trial: Results (Survival Free of CV Death) SHEP Follow Up Trial: Results (Survival Probability of All Cause Mortality) JAMA 2011; 306 (23): JAMA 2011; 306 (23): Hypertension In the Elderly: The J Curve When it comes to BP lowering, how much is too much? INVEST Study 2011 Consensus Recommendations: SBP < 130 mm Hg and DBP < 65 mm Hg should be avoided d in patients t 80 yrs old. Am J Med 2010; 123: How should hypertensive elderly patients be managed? Interdisciplinary Approach This management is fostered by behavioral interventions that focus on re enforcement techniques to enhance engagement of elderly individuals in their own care employing a team The team should ideally be composed of clinical pharmacists, nurses, physician assistants, clinical psychologists, and others (as necessary). 5

6 Nonpharmacologic Recommendations Weight reduction DASH eating plan Dietary sodium restriction Increased physical activity Moderation of alcohol consumption Smoking cessation JNC-VII Complete Report 2003 NIH Publication Prior to initiating pharmacotherapy, consider: QOL and cognitive function Age related physiologic changes Other meds the patient may be currently taking Initiation of drug therapy Initial drug should be started at the lowest dose and gradually depending on the BP response to the maximum tolerated dose. If BP response to the ini al drug is inadequate a er reaching full dose, a 2 nd drug from another class should be added, provided the initial drug is tolerated. Initiation of drug therapy If no therapeutic response or significant adverse effects, a drug from another class should be substituted. If a diuretic is not the initial drug, it s usually indicated as the 2 nd drug. If BP response is inadequate a er reaching the full dose of 2 classes of drugs, a 3 rd agent from another class should be added. If BP is >20/10 mm Hg above goal, drug therapy should generally be initiated with 2 agents one of which should be a thiazide diuretic; however, in the elderly, treatment must be individualized. Adjustments to meds should not be made until the following are assessed: Compliance Volume status Drug interactions Other drugs/secondary conditions that can exacerbate HTN Lifestyle factors Adverse effect profile Pseudoresistance Patients 80 yrs, SBP 150 mm Hg may be acceptable for dx HTN and treatment target If SBP <150 mm Hg can be safely achieved: May consider SBP < 140 mm Hg. Also SBP mm Hg is reasonable. If SBP 150 mm Hg with one of the following: -Regimen of 4 drugs -Intolerable adverse -effects -DBP < 65 Lowest safely achieved SBP 150 mm Hg is acceptable 6

7 TG is an 85 y/o male with a long standing h/o HTN. He takes lisinopril/hctz 10 /25 mg daily and his SBP usually ranges between mm Hg and DBP mm Hg. Which BP goal is the most appropriate? 1. < 140/90 mm Hg 2. < 130/80 mm Hg 3. < 120/80 mm Hg 4. His BP measurements are acceptable Which RCT illustrated CV benefits of a thiazide/ace inhibitor combination in an population of 80+ yr old patients with systolic HTN? 1. SHEP Trial 2. HYVET 3. ACCOMPLISH Trial 4. STOP Study KW is an 85 yr female with newly dx HTN. She was started on amlodipine 5 mg /day 6 wks ago. The medical resident wishes to to 10 mg daily for be er control. Prior to changing the dose, what should be considered? 1. Compliance 2. Able to perform lifestyle modifications 3. Other meds that she takes 4. All of the above How Should We ACCOMPLISH Good Blood Pressure Control In Our VETS? Updates in the Management of Hypertension In the Elderly Antoine T. Jenkins, Pharm.D., BCPS Assistant Professor of Pharmacy Practice Chicago State University College of Pharmacy Internal Medicine Pharmacy Specialist Roseland Community Hospital, Chicago, IL 7

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College

More information

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division

More information

Hypertension Controversies: SPRINTing to New Goals

Hypertension Controversies: SPRINTing to New Goals Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Hypertension in the very old. Objectives: Clinical Perspective

Hypertension in the very old. Objectives: Clinical Perspective Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

Hypertension and Cholesterol in the Elderly

Hypertension and Cholesterol in the Elderly Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden

More information

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014 HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted

More information

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Hypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center

Hypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative

More information

Conflicts of Interest. Hypertension Guidelines Have Your Blood Pressure Up? Learning Objectives-Technician. Learning Objectives-Pharmacist

Conflicts of Interest. Hypertension Guidelines Have Your Blood Pressure Up? Learning Objectives-Technician. Learning Objectives-Pharmacist Conflicts of Interest Hypertension Guidelines Have Your Blood Pressure Up? Diana Isaacs, PharmD, BCPS, BC-ADM, has no actual or potential conflicts of interest in relation to this program. Diana Isaacs,

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Randomized Design of ALLHAT BP Trial

Randomized Design of ALLHAT BP Trial Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive

More information

The New Hypertension Guidelines

The New Hypertension Guidelines The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts

More information

Talking about blood pressure

Talking about blood pressure Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:

More information

Objective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel

Objective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step

More information

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016 Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34

More information

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

Isolated Systolic Hypertension in the elderly. Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg

Isolated Systolic Hypertension in the elderly. Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Isolated Systolic Hypertension in the elderly Daniel Hayoz Clinique de Médecine Interne HFR-Hôpital Cantonal Fribourg Case no 1 Man aged 75, from Kosovo, in CH since 1.5 years Former smoker (45 PY) BP:

More information

Jackson T. Wright, Jr. MD, PhD

Jackson T. Wright, Jr. MD, PhD DIFFERENTIAL EFFECTS OF BLOOD PRESSURE MEDICATIONS IN BLACK PATIENTS Jackson T. Wright, Jr. MD, PhD Professor of Medicine Program Director, WT Dahms MD Clinical Research Unit Clinical and Translational

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

Conflicts of Interest. Hypertension Guidelines Have Your Blood Pressure Up? Learning Objectives-Technician. Learning Objectives-Pharmacist

Conflicts of Interest. Hypertension Guidelines Have Your Blood Pressure Up? Learning Objectives-Technician. Learning Objectives-Pharmacist Conflicts of Interest Hypertension Guidelines Have Your Blood Pressure Up? Diana Isaacs, PharmD, BCPS, BC-ADM, has no actual or potential conflicts of interest in relation to this program. Diana Isaacs,

More information

Hypertension Putting the Guidelines into Practice. Andy Ignaszewski MD FRCPC UBC/PHC Cardiology

Hypertension Putting the Guidelines into Practice. Andy Ignaszewski MD FRCPC UBC/PHC Cardiology Hypertension 2017 Putting the Guidelines into Practice Andy Ignaszewski MD FRCPC UBC/PHC Cardiology Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,

More information

Creative blood pressure management: whys and the tricks

Creative blood pressure management: whys and the tricks Creative blood pressure management: whys and the tricks Cynthia D. Caraballo-Hunt, MD Kaiser/OHSU Family Medicine Faculty Beaverton Medical Office NW Permanente, Portland, OR Objectives 1. Describe current

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

Causes of Poor BP control Rates

Causes of Poor BP control Rates Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular

More information

Hypertension Management in Diabetic Patients

Hypertension Management in Diabetic Patients Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension

More information

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Antihypertensive Combinations

Antihypertensive Combinations This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations

More information

Hypertension in the Geriatric Patient: Review and Update

Hypertension in the Geriatric Patient: Review and Update Hypertension in the Geriatric Patient: Review and Update Donna Miller, MD Senior Associate Consultant, Division of Hospital Internal Medicine Instructor in Medicine CAPA Annual Conference October 24, 2015

More information

Update in Outpatient Medicine JNC 8, Hypertension and More

Update in Outpatient Medicine JNC 8, Hypertension and More Update in Outpatient Medicine JNC 8, Hypertension and More March 6 th 2015 Robert Gluckman, MD, FACP CMO Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers Squibb GE Proctor

More information

Hypertension Guidelines JNC Recommendations. Robert E. Bulow DO FACOI, FACC

Hypertension Guidelines JNC Recommendations. Robert E. Bulow DO FACOI, FACC Hypertension Guidelines JNC Recommendations Robert E. Bulow DO FACOI, FACC None Disclosures Question At what blood pressure should pharmacologic therapy be initiated in the non diabetic pt with age greater

More information

Lowering blood pressure in 2003

Lowering blood pressure in 2003 UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor

More information

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest

More information

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers. Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS

More information

Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice

Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Faculty Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular Health Program Division of General Internal Medicine

More information

Conflict of Interest Disclosure

Conflict of Interest Disclosure HYPERTENSION UPDATE: NEW JNC 8 Guideline vs OLD Federal Motor Carrier Safety Regulations PLEASE STAND BY WEBINAR WILL BEGIN AT 12:00 PM PST FOR AUDIO: CALL 866-740-1260 / ACCESS CODE: 764-4915# Conflict

More information

Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic

Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic Dr. Dao Man Chi Resident Department of Family Medicine and Primary Health Care, KWC HA Convention 2014 Introduction

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:

More information

Blood Pressure Treatment in 2018

Blood Pressure Treatment in 2018 Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management

More information

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Blood Pressure Management

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Blood Pressure Management CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Blood Pressure Management Wein T, Gladstone D (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2017 Heart and Stroke Foundation September

More information

Guide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital

Guide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Disclosures None Objectives Describe the new hypertension staging and blood pressure goals and

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?

1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? Jeff D. Williamson, MD, MHS Chief, Geriatric Medicine Sticht Center on Aging 1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? 2. Are

More information

Drug Class Review on Calcium Channel Blockers FINAL REPORT

Drug Class Review on Calcium Channel Blockers FINAL REPORT Drug Class Review on Calcium Channel Blockers FINAL REPORT September 2003 TABLE OF CONTENTS Introduction 5 Scope and Key Questions 6 Methods 6 Literature Search 6 Study Selection 6 Data Abstraction 7 Validity

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Recent Hypertension Guidelines

Recent Hypertension Guidelines Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH February 19, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National Committee

More information

Choice of therapy in esse... http://www.uptodate.co... Page 1 of 28 Official reprint from UpToDate www.uptodate.com Print Back Choice of therapy in essential hypertension: Recommendations Authors Norman

More information

LIPIDS ADVANCES IN PRIMARY CARE: STRATEGY TOPICS PRACTICE-CHANGING PAPERS FROM THE PAST YEAR. Topics:

LIPIDS ADVANCES IN PRIMARY CARE: STRATEGY TOPICS PRACTICE-CHANGING PAPERS FROM THE PAST YEAR. Topics: ADVANCES IN PRIMARY CARE: PRACTICE-CHANGING PAPERS FROM THE PAST YEAR Michael G. Shlipak, MD MPH Chief, Division of General Internal Medicine San Francisco VA Medical Center Professor In-Residence Departments

More information

Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study

Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study Antonio Coca MD, PhD, FRCP, FESC Council on Hypertension. European Society of Cardiology Hypertension and Vascular Risk Unit. Department of

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia?

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? 2012. 4. 20-21 춘계심장학회 _ 부산 Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? Jeong Bae Park, MD, PhD Cardiology, Cheil General Hospital, Kwandong University, Seoul, Korea The Pulse : revived

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College

More information

Best Practices in the Management of Hypertension in Older Adults

Best Practices in the Management of Hypertension in Older Adults Best Practices in the Management of Hypertension in Older Adults George Dresser, MD, PhD, FRCPC Associate Professor of Medicine Division of Clinical Pharmacology, Western U. Speaker Disclosure Form George

More information

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr

More information

Retour sur le congrès de l AHA 2017

Retour sur le congrès de l AHA 2017 Retour sur le congrès de l AHA 2017 Paul Poirier MD, PhD, FRCPC, FACC, FAHA, FCCS Professeur Faculté de pharmacie Université Laval Responsable du programme de prévention/réadaptation cardiaque Canagliflozin

More information

What s New in HBP Management For 2015? Gregory A. Parkin, MD Physician, Department Chair, Bryner Group at Salt Lake Clinic, Intermountain Healthcare

What s New in HBP Management For 2015? Gregory A. Parkin, MD Physician, Department Chair, Bryner Group at Salt Lake Clinic, Intermountain Healthcare What s New in HBP Management For 2015? Gregory A. Parkin, MD Physician, Department Chair, Bryner Group at Salt Lake Clinic, Intermountain Healthcare Objectives: Describe current goal levels for HTN Review

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

h i g h b l o o d p r e s s u r e

h i g h b l o o d p r e s s u r e h i g h b l o o d p r e s s u r e where are we at? The recent literature has raised doubts about the role of ßblockers for lowering blood pressure and the New Zealand Guidelines Group is updating the Assessment

More information

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ CAD: Statistics CAD is the largest killer of American males and females 13 million Americans have CAD 1.1 million MI s per year Every 26 seconds an American

More information

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting

More information

Overview of the outcome trials in older patients with isolated systolic hypertension

Overview of the outcome trials in older patients with isolated systolic hypertension Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated

More information

Impact of Hypertension Threshold and Goals on Special Populations

Impact of Hypertension Threshold and Goals on Special Populations Impact of Hypertension Threshold and Goals on Special Populations National Lipid Association 2015 Annual Scientific Sessions June 13,2015 Keith C. Ferdinand, MD, FACC,FAHA,FASH,FNLA Professor of Clinical

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

ANTI- HYPERTENSIVE AGENTS

ANTI- HYPERTENSIVE AGENTS CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario M Paul Anand Consultant Physician, Lady Ratan Tata Medical Centre, M. Karve Road, Cooperage, Mumbai Executive Editor, API Textbook of Medicine Introduction

More information

Sponsored by the National Heart, Lung, and Blood Institute (NHLBI)

Sponsored by the National Heart, Lung, and Blood Institute (NHLBI) 1 U.S. Department of Health and Human Services The Hypertension, Detection, and Follow-up Program (HDFP) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) National

More information

Hypertension and Atrial Fibrillation

Hypertension and Atrial Fibrillation Hypertension and Atrial Fibrillation Sheldon Tobe MD, MScCH (HPTE), FRCPC, FACP, FASH Hypertension and Nephrology HSF/NOSM Chair in Aboriginal and Rural Health Research Professor in Medicine, University

More information